1. Articles in category: Cells and Stem Cells

    1-24 of 228 1 2 3 4 5 6 7 8 9 10 »
    1. New research points to potential targeted treatments of neuroblastoma tumours

      New research points to potential targeted treatments of neuroblastoma tumours

      Genetic variations appear to pre-dispose children to developing certain severe forms of neuroblastoma, according to new research by the University of Chicago Medicine.

      The findings lay the groundwork for developing more targeted treatments for...

      Read Full Article
      Mentions: MYCN
    2. Potential for more targeted treatments of neuroblastoma tumors

      Genetic variations appear to pre-dispose children to developing certain severe forms of neuroblastoma, according to new research. The findings lay the groundwork for developing more targeted treatments for particularly deadly variations of the cancer.

      Read Full Article
      Mentions: MYCN
    3. New research points to potential for more targeted treatments of neuroblastoma tumors

      New research points to potential for more targeted treatments of neuroblastoma tumors

      ( University of Chicago Medical Center ) Genetic variations appear to pre-dispose children to developing certain severe forms of neuroblastoma, according to new research by the University of Chicago Medicine. The findings lay the groundwork for developing more targeted treatments for particularly deadly variations of the cancer.

      Read Full Article
      Mentions: MYCN
    4. CFC1 is a cancer stemness-regulating factor in neuroblastoma.

      CFC1 is a cancer stemness-regulating factor in neuroblastoma.

      Oncotarget. 2017 Jun 13;:

      Authors: Chikaraishi K, Takenobu H, Sugino RP, Mukae K, Akter J, Haruta M, Kurosumi M, Endo TA, Koseki H, Shimojo N, Ohira M, Kamijo T

      Abstract BACKGROUND: Despite the use of aggressive therapy, survival rates among high-risk neuroblastoma (NB) patients remain poor. Cancer stem cells (CSCs) are considered to be critically involved in the recurrence and metastasis of NB and are isolated as NB spheres.

      Read Full Article
      Mentions: Metastasis
    5. Late Effects in Pediatric High-risk Neuroblastoma Survivors After Intensive Induction Chemotherapy Followed by Myeloablative Consolidation Chemotherapy and Triple Autologous Stem Cell Transplants.

      Late Effects in Pediatric High-risk Neuroblastoma Survivors After Intensive Induction Chemotherapy Followed by Myeloablative Consolidation Chemotherapy and Triple Autologous Stem Cell Transplants.

      J Pediatr Hematol Oncol. 2017 May 23;:

      Authors: Armstrong AE, Danner-Koptik K, Golden S, Schneiderman J, Kletzel M, Reichek J, Gosiengfiao Y

      Read Full Article
      Mentions: Chemotherapy
    6. Incorporation of high-dose (131)I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study.

      "Incorporation of high-dose 131I-MIBG treatment into tandem HDCT/auto-SCT could reduce short- and long-term toxicities associated with TBI, without jeopardizing the survival rate."

      Read Full Article
    7. Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients with Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma

      Phase III

      Treatment

      Not yet active

      365 days to 30 years

      ANBL1531

      NCI-2016-01734, NCT03126916

      This partially randomized phase III trial studies iobenguane I-131 or crizotinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells.

      Read Full Article
      Mentions: Treatment INRG ALK
    8. The Transcription Regulator Krüppel-Like Factor 4 and Its Dual Roles of Oncogene in Glioblastoma and Tumor Suppressor in Neuroblastoma.

      The Transcription Regulator Krüppel-Like Factor 4 and Its Dual Roles of Oncogene in Glioblastoma and Tumor Suppressor in Neuroblastoma.

      For Immunopathol Dis Therap. 2016;7(1-2):127-139

      Authors: Ray SK

      Abstract The Krüppel-like factor 4 (KLF4) gene is located on chromosome 9q31.

      Read Full Article
    9. Anti-cancer stemness and anti-invasive activity of bitter taste receptors, TAS2R8 and TAS2R10, in human neuroblastoma cells.

      Anti-cancer stemness and anti-invasive activity of bitter taste receptors, TAS2R8 and TAS2R10, in human neuroblastoma cells.

      PLoS One. 2017;12(5):e0176851

      Authors: Seo Y, Kim YS, Lee KE, Park TH, Kim Y

      Abstract Neuroblastoma (NB) originates from immature neuronal cells and currently has a poor clinical outcome. NB cells possess cancer stem cells (CSCs) characteristics that facilitate the initiation of a tumor, as well as its metastasis.

      Read Full Article
      Mentions: Metastasis
    10. High-Risk Neuroblastoma with Metastases to Bilateral Kidneys at Diagnosis.

      High-Risk Neuroblastoma with Metastases to Bilateral Kidneys at Diagnosis.

      Case Rep Pediatr. 2017;2017:5375091

      Authors: Yoshikawa T, Tanizawa A, Suzuki K, Ikeda K, Nomura E, Maeda Y, Tanaka N, Yamada K, Sakai Y, Imamura Y, Ohshima Y

      Abstract Renal metastasis at diagnosis with neuroblastoma is rare. We present a 14-month-old boy who was diagnosed with high-risk neuroblastoma with multiple metastases, including bilateral kidneys.

      Read Full Article
      Mentions: Metastasis
    11. Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.

      Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.

      Cochrane Database Syst Rev. 2017 Apr 21;4:CD010349

      Authors: Kraal KC, van Dalen EC, Tytgat GA, Van Eck-Smit BL

      Abstract BACKGROUND: Patients with newly diagnosed high-risk (HR) neuroblastoma (NBL) still have a poor outcome, despite multi-modality intensive therapy.

      Read Full Article
      Mentions: MIBG
    12. Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma

      Conditions :   Childhood Ganglioneuroblastoma;   Childhood Neuroblastoma;   NMYC Gene Amplification;   Recurrent Neuroblastoma Interventions :   Biological: Aldesleukin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Cyclophosphamide;   Drug: Dexrazoxane Hydrochloride;   Biological: Dinutuximab;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide Phosphate;   Radiation: External Beam Radiation Therapy;   Radiation: Iobenguane I-131;   Drug: Isotretinoin;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Pharmacological Study;   Biological: Sargramostim;   Procedure: Therapeutic Conventional Surgery;   Drug: Thiotepa;   Drug: Topotecan Hydrochloride;   Drug: Vincristine Sulfate Sponsors :   Children's Oncology Group;   National Cancer Institute (NCI) Not yet recruiting - verified April 2017

      Read Full Article
    13. Management of Neuroblastoma: ICMR Consensus Document.

      Management of Neuroblastoma: ICMR Consensus Document.

      Indian J Pediatr. 2017 Apr 03;:

      Authors: Bansal D, Totadri S, Chinnaswamy G, Agarwala S, Vora T, Arora B, Prasad M, Kapoor G, Radhakrishnan V, Laskar S, Kaur T, Rath GK, Bakhshi S

      Abstract Neuroblastoma (NBL) is the most common extra-cranial solid tumor in childhood. High-risk NBL is considered challenging and has one of the least favourable outcomes amongst pediatric cancers.

      Read Full Article
      Mentions: Staging Relapse MYCN
    14. Physical and social characteristics and support needs of adult female childhood cancer survivors who underwent hormone replacement therapy.

      Physical and social characteristics and support needs of adult female childhood cancer survivors who underwent hormone replacement therapy.

      Int J Clin Oncol. 2017 Mar 31;:

      Authors: Tomioka A, Maru M, Kashimada K, Sakakibara H

      Abstract BACKGROUND: Female childhood cancer survivors who develop gonadal dysfunction require female hormone replacement therapy (HRT) from puberty until menopause. However, the support provided in such cases has not been studied.

      Read Full Article
    15. Optimization of a Neural Stem-Cell-Mediated Carboxylesterase/Irinotecan Gene Therapy for Metastatic Neuroblastoma.

      Optimization of a Neural Stem-Cell-Mediated Carboxylesterase/Irinotecan Gene Therapy for Metastatic Neuroblastoma.

      Mol Ther Oncolytics. 2017 Mar 17;4:67-76

      Authors: Gutova M, Goldstein L, Metz M, Hovsepyan A, Tsurkan LG, Tirughana R, Tsaturyan L, Annala AJ, Synold TW, Wan Z, Seeger R, Anderson C, Moats RA, Potter PM, Aboody KS

      Read Full Article
    16. HLA-E inhibitor enhances the killing of neuroblastoma stem cells by co-cultured dendritic cells and cytokine-induced killer cells loaded with membrane-based microparticles.

      HLA-E inhibitor enhances the killing of neuroblastoma stem cells by co-cultured dendritic cells and cytokine-induced killer cells loaded with membrane-based microparticles.

      Am J Cancer Res. 2017;7(2):334-345

      Authors: Zhen Z, Yang K, Ye L, You Z, Chen R, Liu Y, He Y

      Read Full Article
    17. Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients.

      Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients.

      Eur J Cancer. 2017 Mar 19;76:188-196

      Authors: Kraal KC, Bleeker GM, van Eck-Smit BL, van Eijkelenburg NK, Berthold F, van Noesel MM, Caron HN, Tytgat GA

      Read Full Article
      Mentions: GPOH MIBG
    18. A c-Myc-regulated stem cell-like signature in high-risk neuroblastoma: A systematic discovery (Target neuroblastoma ESC-like signature).

      A c-Myc-regulated stem cell-like signature in high-risk neuroblastoma: A systematic discovery (Target neuroblastoma ESC-like signature).

      Sci Rep. 2017 Dec;7(1):41

      Authors: Yang XH, Tang F, Shin J, Cunningham JM

      Abstract c-Myc dysregulation is hypothesized to account for the 'stemness' - self-renewal and pluripotency - shared between embryonic stem cells (ESCs) and adult aggressive tumours.

      Read Full Article
    19. Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma.

      Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma.

      BMC Cancer. 2017 Feb 24;17(1):156

      Authors: Bayat Mokhtari R, Baluch N, Ka Hon Tsui M, Kumar S, S Homayouni T, Aitken K, Das B, Baruchel S, Yeger H

      Abstract BACKGROUND: Neuroblastoma (NB), a tumor of the primitive neural crest, despite aggressive treatment portends a poor long-term survival for patients with advanced high stage NB. New treatment strategies are required.

      Read Full Article
      Mentions: Treatment
    20. Didymin: an orally active citrus flavonoid for targeting neuroblastoma.

      Didymin: an orally active citrus flavonoid for targeting neuroblastoma.

      Oncotarget. 2017 Feb 08;:

      Authors: Singhal SS, Singhal S, Singhal P, Singhal J, Horne D, Awasthi S

      Abstract Neuroblastoma, a rapidly growing yet treatment responsive cancer, is the third most common cancer of children and the most common solid tumor in infants. Unfortunately, neuroblastoma that has lost p53 function often has a highly treatment-resistant phenotype leading to tragic outcomes.

      Read Full Article
      Mentions: Treatment MYCN
    21. Two investigational antitumor agents work better together against MPNST and neuroblastoma

      Two investigational antitumor agents work better together against MPNST and neuroblastoma

      Two investigational agents, Aurora A kinase inhibitor (alisertib) and HSV1716, a virus derived from HSV-1 and attenuated by the deletion of RL1, have shown some antitumor efficacy in early clinical trials as monotherapies. A new study published last week in Oncotarget, however, demonstrates that the combined usage of the agents results in significantly increased antitumor efficacy in models of malignant peripheral nerve sheath tumor (MPNST) and neuroblastoma.

      Read Full Article
    1-24 of 228 1 2 3 4 5 6 7 8 9 10 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles